Spyre Therapeutics, Inc. SYRE
Set alert
96.56 USD -2.40 -2.43%
At close · Oct 30
96.45 -0.11 -0.11%
After hours · Oct 30, 4:00 PM ET
94.68 Day range 98.96
22.18 52-week range 108.92
- YTD
- +194.75%
- 1 year
- +298.02%
- Open
- 96.78
- Prev close
- 98.96
- Mkt cap
- 9.02B
- Vol
- 661.13K
- Avg vol
- 1.21M
- EPS
- -1.92
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 94.68
- High
- 98.96
- Forward P/E
- -27.55
- Beta
- 3.11
- Short ratio
- 7.98
- Inst. own
- 108.53%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 90.28
- 200-d avg
- 72.91
- 1y target
- 122.33
5D chart
Signals (103)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 9:30 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:30 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 1 day ago |
| SMA: Bullish | Oct 29, 3:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:15 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:00 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:55 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 2 days ago |
| RSI: Oversold | Oct 29, 2:35 PM | 2 days ago |
| RSI: Oversold | Oct 29, 2:10 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 1:30 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:25 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 1:15 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 1:10 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 1:00 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 11:40 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 11:20 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:15 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:00 AM | 2 days ago |
| SMA: Bearish | Oct 29, 9:55 AM | 2 days ago |
| MACD: Buy Signal | Oct 28, 3:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:05 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:20 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:15 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:05 PM | 3 days ago |
| RSI: Oversold | Oct 28, 12:45 PM | 3 days ago |
| SMA: Bearish | Oct 28, 11:45 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:25 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:25 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:10 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 10:45 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:15 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:00 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:55 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 9:45 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:40 AM | 3 days ago |
| RSI: Overbought | Oct 27, 3:55 PM | 4 days ago |
| RSI: Overbought | Oct 27, 3:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:05 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:25 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 12:05 PM | 4 days ago |
| RSI: Overbought | Oct 27, 10:40 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 4 days ago |
| RSI: Overbought | Oct 27, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 26, 3:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:30 PM | 5 days ago |
| RSI: Oversold | Oct 26, 3:00 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:25 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:15 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:10 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:10 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:00 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:40 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:10 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:05 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:00 PM | 5 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 5 days ago |
| RSI: Overbought | Oct 26, 11:10 AM | 5 days ago |
| SMA: Bullish | Oct 26, 11:05 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:55 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:50 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:40 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:35 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 5 days ago |
Key statistics
- Market cap
- 9.02B
- Enterprise value
- 7.73B
- Trailing P/E
- 0.00
- Forward P/E
- -27.55
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 8.91
- EPS (TTM)
- -1.92
- Beta
- 3.11
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -89.05M
- Total cash
- 1.15B
- Total debt
- 0
- Return on equity
- -22.98%
- Shares outstanding
- 93.45M
- Short % of float
- 14.25%
- 50-day average
- 90.28
- 200-day average
- 72.91
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 122.33 +26.7% upside
Now 96.56
- Target (low)
- 110.00
- Target (mean)
- 122.33
- Target (high)
- 130.00
Ratings (0m) 18 17 buy · 1 hold · 0 sell
- Strong buy1
- Buy16
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate -0.83521.
Financials — quick view
SYRE Revenue — quarterly 0
SYRE Net income — quarterly -36.20M
SYRE EPS — quarterly -0.36
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -0.78502 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | -0.75885 | -0.36 | +0.40 | +52.56% |
| May 5, 2026 | Mar 31, 2026 | -0.66 | -0.74 | -0.08 | -12.12% |
| Feb 19, 2026 | Dec 31, 2025 | -0.66 | -0.70 | -0.04 | -6.06% |
| Nov 4, 2025 | Sep 30, 2025 | -0.76076 | -0.15 | +0.61 | +80.28% |
| Aug 5, 2025 | Jun 30, 2025 | -0.73 | -0.49 | +0.24 | +32.88% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2026 | BTIG | reit | Buy | Buy |
| Oct 12, 2026 | UBS | init | — | Buy |
| Oct 1, 2026 | JP Morgan | init | — | Overweight |
| Oct 1, 2026 | BTIG | reit | Buy | Buy |
| Sep 9, 2026 | Wedbush | reit | Outperform | Outperform |
| Sep 8, 2026 | BTIG | reit | Buy | Buy |
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- spyre.com
News
- BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target
- Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
- UBS Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $120
- Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination Potential
- Crude Oil Edges Lower; Lamb Weston Shares Surge Following Upbeat Q1 Earnings
- Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
- Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
- Spyre (NASDAQ: SYRE) legal chief trims stake in planned share sale
- Spyre Therapeutics Announces Grants of Inducement Awards
- Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up – Should You Buy?
Your note
Sign in to keep a note on SYRE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALBERS JEFFREY W | Director | Sale | Aug 6, 2026 | 0 |
| BURROWS SCOTT L. | Chief Financial Officer | Sale | Sep 1, 2026 | 79,762 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Unknown | Sale | Jun 22, 2026 | 0 |
| HENDERSON MICHAEL THOMAS | Director | Sale | Jun 21, 2026 | 68,606 |
| KING-JONES HEIDY | Officer | Sale | Sep 1, 2026 | 2,845 |
| SLOAN SHELDON | Officer | Sale | Jun 30, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 12.78% | 13,026,187 | 1.26B | Jun 29, 2026 |
| Blackrock Inc. | 6.38% | 6,506,605 | 628.28M | Jun 29, 2026 |
| Perceptive Advisors Llc | 4.24% | 4,319,496 | 417.09M | Jun 29, 2026 |
| RTW Investments LP | 4.17% | 4,251,996 | 410.57M | Jun 29, 2026 |
| Paradigm Biocapital Advisors LP | 3.77% | 3,840,778 | 370.87M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.38% | 3,448,681 | 333.00M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.71% | 2,760,132 | 266.52M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.44% | 2,482,298 | 239.69M | Jun 29, 2026 |
| SmallCap World Fund Inc | 2.21% | 2,247,758 | 217.04M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.95% | 1,982,310 | 191.41M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.67% | 1,699,846 | 164.14M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 0.88% | 896,559 | 86.57M | Jun 29, 2026 |